Anaptysbio (ANAB) Assets Average (2017 - 2026)
Anaptysbio posted quarterly Assets Average of $347.0 million for Q1 2026, down 23.38% year-on-year from $452.9 million in Q1 2025, and down 3.26% on a QoQ basis from $358.7 million in Q4 2025.
Anaptysbio (ANAB) has 10 years of Assets Average data on file, last reported at $347.0 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 23.38% year-over-year to $347.0 million; the trailing twelve-month figure through Mar 2026 stood at $347.0 million (down 23.38% YoY), and the FY2025 full-year result was $424.1 million, down 9.4% from the prior year.
- Assets Average for Q1 2026 stood at $347.0 million, down from $358.7 million in the prior quarter.
- Across five years, Assets Average topped out at $634.1 million in Q1 2022 and bottomed at $344.2 million in Q3 2025.
- The 5-year median for Assets Average is $469.9 million (2023), against an average of $484.6 million.
- The widest annual swing landed in 2022, when Assets Average jumped 56.0%; it then declined 26.58% in 2025.
- A 5-year view of Assets Average shows it stood at $614.4 million in 2022, then dropped by 23.53% to $469.9 million in 2023, then grew by 3.99% to $488.6 million in 2024, then slipped by 26.58% to $358.7 million in 2025, then dropped by 3.26% to $347.0 million in 2026.
- The last three Assets Average figures came in at $347.0 million (Q1 2026), $358.7 million (Q4 2025), and $344.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | 347.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 347.04 Mn |
| Dec 31, 2025 | 358.75 Mn |
| Sep 30, 2025 | 344.17 Mn |
| Jun 30, 2025 | 378.65 Mn |
| Mar 31, 2025 | 452.94 Mn |
| Dec 31, 2024 | 488.63 Mn |
| Sep 30, 2024 | 460.40 Mn |
| Jun 30, 2024 | 416.61 Mn |
| Mar 31, 2024 | 429.11 Mn |
| Dec 31, 2023 | 469.86 Mn |
| Sep 30, 2023 | 502.21 Mn |
| Jun 30, 2023 | 534.45 Mn |
| Mar 31, 2023 | 581.09 Mn |
| Dec 31, 2022 | 614.44 Mn |
| Sep 30, 2022 | 611.18 Mn |
| Jun 30, 2022 | 614.51 Mn |
| Mar 31, 2022 | 634.12 Mn |
| Dec 31, 2021 | 533.70 Mn |
| Sep 30, 2021 | 425.45 Mn |
| Jun 30, 2021 | 411.49 Mn |
| Mar 31, 2021 | 406.49 Mn |
| Dec 31, 2020 | 400.65 Mn |
| Sep 30, 2020 | 393.25 Mn |
| Jun 30, 2020 | 412.99 Mn |
| Mar 31, 2020 | 429.72 Mn |
| Dec 31, 2019 | 443.35 Mn |
| Sep 30, 2019 | 465.83 Mn |
| Jun 30, 2019 | 487.19 Mn |
| Mar 31, 2019 | 501.61 Mn |
| Dec 31, 2018 | 516.06 Mn |
| Sep 30, 2018 | 414.57 Mn |
| Jun 30, 2018 | 310.43 Mn |
| Mar 31, 2018 | 322.10 Mn |
| Dec 31, 2017 | 225.65 Mn |
| Sep 30, 2017 | 126.18 Mn |
| Jun 30, 2017 | 130.76 Mn |
| Mar 31, 2017 | 96.65 Mn |